Company intelligence / Profile preview

ImmUnity

Culver City, California, United States

Ownership: Private
Development stage: Other

Overview

ImmunityBio has received FDA Breakthrough Therapy designation and first approval (April 2024) for ANKTIVA (nogapendekin alfa inbakicept-pmln, N-803) for BCG-unresponsive non-muscle invasive bladder cancer. The pipeline includes 27 clinical trials across 13 indications, with at least one product approved and multiple Phase 2/3 programs for solid tumors, viral diseases, and immune therapy innovations[1][4].

Therapeutic areas: OncologyInfectious Diseases
Modalities: Monoclonal antibodyAntibody-cytokine fusion proteinCell therapyVaccineGene therapyRecombinant proteinTherapeutic vaccineProphylactic vaccine
Industry: Biotech

Partnerships

National Cancer Institute (NCI)Etubics Corp.

Beyond the preview

Go deeper on ImmUnity.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmUnity.

Explore the full profile